| |
Preclinical |
P1 |
P2 |
P3 |
Regulatory Review |
Approval |
|
| sCT nasal U.S. (Fortical®) |
| | | | | | Upsher Smith |
| sCT nasal |
| | | | | | Outside US |
| sCT oral |
| | | | | | Worldwide |
| PTH analogs oral |
| | | | | | GSK |
| Obesity/Satiety (UGP281) |
| | | | | | Worldwide |
| SDBG* |
| | | | | | Worldwide |
| sCT combination drugs |
| | | | | | Worldwide |
| Annexin peptides |
| | | | | | Worldwide |
